Folate pathway restoration

"Folate pathway restoration" is not the name of a specific molecule or receptor but refers broadly to therapeutic strategies aimed at correcting deficiencies or dysfunctions in the folate metabolic pathway. The folate pathway encompasses multiple enzymes—including dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TYMS), serine hydroxymethyltransferase—and transporters such as reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT)[1][2][3]. This network is essential for one-carbon transfer reactions required for nucleotide biosynthesis, amino acid interconversion, methylation processes critical for gene expression regulation, and overall cellular proliferation. Disruption of this pathway by genetic polymorphisms or drug inhibition can lead to diseases such as cancer, cardiovascular disease due to hyperhomocysteinemia, neural tube defects in pregnancy due to impaired fetal development from low maternal folates, and neurodevelopmental disorders. Drugs like methotrexate target this metabolic network by inhibiting DHFR; others interfere with different steps. Restoration approaches may involve supplementation with active forms of folates or targeting specific enzymes genetically deficient in certain populations. Note: "Folate pathway restoration" does not refer to a single canonical molecular target but rather an entire biochemical process involving several proteins/enzymes; thus it is not considered a standard therapeutic target entity per se.

Other names

Folate metabolismFolate cycleOne-carbon metabolismFolic acid pathway

Inhibition of dihydrofolate reductase (DHFR) blocks conversion of folic acid to tetrahydrofolate, disrupting nucleotide synthesis and cell division